Gut bacteria drug shows promise against blood disorder
NCT ID NCT03820817
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested whether the oral antibiotic rifaximin can reduce abnormal proteins in people with monoclonal gammopathy, a condition that can lead to blood cancers. Fifty adults with different types of gammopathy took the drug to see if it lowered their immunoglobulin levels by at least 25%. The goal was to find a new way to control the disease by targeting bacteria in the gut.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GAMMOPATHY IGG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive drug outperform standard therapy in waldenstrom macroglobulinemia?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a multiple myeloma drug shield the kidneys in MGRS?
- Smartwatches track hidden heart risk in blood cancer patients
- Can a tailored exercise and diet plan beat cancer fatigue?
- Gene clues may unlock new treatments for bone marrow cancer